Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax in Colorectal Cancer

12-Jul-2012 - United Kingdom

Oxford BioMedica plc announced that its partners at Cardiff University, Wales (UK) have initiated a Phase II trial to assess the safety and immunological activity of TroVax®, a therapeutic vaccine developed by Oxford BioMedica, in patients with inoperable metastatic colorectal cancer (CRC).  The study will be funded by Cardiff University, with some funding awarded by Cancer Research Wales, and Oxford BioMedica will provide TroVax®.  The trial is supported by the Experimental Cancer Medicine Centre (ECMC), Cardiff.

The randomised, open-label Phase II study, entitled “TaCTiCC” (TroVax® and Cyclophosphamide Treatment in Colorectal Cancer), builds on four previous Phase I/II trials conducted by Oxford BioMedica where TroVax® was given to patients with CRC, in addition to research into CRC undertaken by Dr Andrew Godkin and Dr Awen Gallimore at Cardiff University, Wales.  Led by Dr Andrew Godkin, the study will enrol up to 54 patients with inoperable metastatic CRC.  The study will evaluate whether TroVax®, administered alone or in combination with cyclophosphamide, is effective in the treatment of CRC.  The study will assess anti-5T4 immune responses following treatment, in addition to secondary measures of clinical benefit including progression-free survival, objective response rate and overall survival.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance